Total Payments
$1.2M
2024 Payments
$52,239
Companies
34
Transactions
617
Medicare Patients
590
Medicare Billing
$174,419
Payment Breakdown by Category
Consulting$595,761 (49.2%)
Other$430,386 (35.5%)
Travel$165,405 (13.7%)
Food & Beverage$10,905 (0.9%)
Research$9,294 (0.8%)
Education$6.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $595,761 | 135 | 49.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $397,923 | 114 | 32.8% |
| Travel and Lodging | $165,405 | 186 | 13.7% |
| Honoraria | $14,830 | 2 | 1.2% |
| Food and Beverage | $10,905 | 162 | 0.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $10,610 | 2 | 0.9% |
| Unspecified | $9,294 | 11 | 0.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,023 | 2 | 0.3% |
| Charitable Contribution | $3,000 | 1 | 0.2% |
| Education | $6.80 | 2 | 0.0% |
Payments by Type
General
$1.2M
606 transactions
Research
$9,294
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $460,992 | 196 | $0 (2023) |
| Celgene Corporation | $175,639 | 93 | $0 (2019) |
| Ipsen Biopharmaceuticals, Inc | $92,157 | 37 | $0 (2022) |
| ABBVIE INC. | $57,871 | 26 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $54,291 | 39 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $53,174 | 42 | $0 (2024) |
| Incyte Corporation | $52,696 | 30 | $0 (2022) |
| AstraZeneca UK Limited | $42,247 | 25 | $0 (2024) |
| Exelixis Inc. | $24,254 | 23 | $0 (2021) |
| Agios Pharmaceuticals, Inc. | $24,066 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $52,239 | 32 | ABBVIE INC. ($30,539) |
| 2023 | $53,209 | 32 | AbbVie Inc. ($27,332) |
| 2022 | $38,153 | 23 | Incyte Corporation ($16,113) |
| 2021 | $182,920 | 64 | Eisai Inc. ($59,765) |
| 2020 | $282,534 | 65 | Eisai Inc. ($168,523) |
| 2019 | $210,068 | 128 | EISAI INC. ($131,423) |
| 2018 | $214,271 | 165 | Eisai Inc. ($79,828) |
| 2017 | $178,363 | 108 | Celgene Corporation ($102,677) |
All Payment Transactions
617 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $2,749.94 | General |
| Category: Oncology | ||||||
| 12/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $879.54 | General |
| Category: Oncology | ||||||
| 12/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $388.51 | General |
| Category: Oncology | ||||||
| 12/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | Cash or cash equivalent | $48.50 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $9,355.64 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $430.00 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $31.25 | General |
| 12/08/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $427.93 | General |
| 12/08/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $238.33 | General |
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,010.00 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $271.64 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $271.64 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $104.94 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $104.94 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $78.15 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $22.10 | General |
| 09/17/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $17.19 | General |
| 06/28/2024 | AstraZeneca Pharmaceuticals LP | — | Charitable Contribution | In-kind items and services | $3,000.00 | General |
| 06/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 03/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $14,117.35 | General |
| 03/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 03/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $338.65 | General |
| 03/04/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $15.37 | General |
| 02/13/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $7,538.25 | General |
| 02/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $701.68 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) | SERVIER AFFAIRES MEDICALES | $3,164 | 3 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB VERSUS SORAFENIB IN PATIENTS WITH UNTREATED ADVANCED HEPATOCELLULAR CARCINOMA HCC | F. Hoffmann-La Roche AG | $2,142 | 3 |
| MY PATHWAY AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMABPERTUZUMAB, ERLOTINIB, VEMURAFENIBCOBIMETINIB, VISMODEGIB , ALECTINIB AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS | F. Hoffmann-La Roche AG | $2,006 | 1 |
| STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) | Servier BioInnovation | $1,310 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $673.21 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 189 | 501 | $300,460 | $46,759 |
| 2022 | 3 | 140 | 434 | $269,450 | $43,962 |
| 2021 | 3 | 124 | 520 | $308,350 | $51,294 |
| 2020 | 5 | 137 | 418 | $228,115 | $32,405 |
Total Patients
590
Total Services
1,873
Medicare Billing
$174,419
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 73 | 346 | $188,570 | $28,710 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 66 | $48,180 | $7,676 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $47,025 | $7,235 | 15.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 31 | $11,160 | $2,195 | 19.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $5,525 | $942.50 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 334 | $182,030 | $29,128 | 16.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 44 | 44 | $45,980 | $7,512 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 56 | $41,440 | $7,322 | 17.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 60 | 435 | $237,075 | $38,659 | 16.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 54 | $38,880 | $7,249 | 18.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $32,395 | $5,386 | 16.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 54 | 304 | $158,080 | $21,998 | 13.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 27 | 48 | $33,120 | $4,844 | 14.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $25,740 | $4,062 | 15.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 29 | $10,295 | $1,369 | 13.3% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 11 | 11 | $880.00 | $132.11 | 15.0% |
About Dr. Ghassan Abou-Alfa, MD
Dr. Ghassan Abou-Alfa, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1134190168.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ghassan Abou-Alfa, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $52,239 received in 2024. These payments were reported across 617 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($595,761).
As a Medicare-enrolled provider, Abou-Alfa has provided services to 590 Medicare beneficiaries, totaling 1,873 services with total Medicare billing of $174,419. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/28/2006
- Last Updated 04/07/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1134190168
Products in Payments
- Lenvima (Drug) $460,992
- Abraxane (Drug) $127,699
- ONIVYDE (Drug) $77,273
- Nexavar (Drug) $50,843
- TIBSOVO (Drug) $34,506
- IMFINZI (Biological) $30,775
- TECENTRIQ (Biological) $25,222
- IMFINZI (Drug) $21,107
- PEMAZYRE (Drug) $17,400
- OPDIVO (Biological) $14,227
- SIR-Spheres Microspheres (Device) $13,661
- CABOMETYX (Drug) $12,495
- Cabometyx (Drug) $11,178
- Onivyde (Drug) $10,134
- Tibsovo (Drug) $8,599
- Avastin (Biological) $8,214
- ONCOZENE (Device) $5,534
- RF 3000 (Device) $5,085
- TRUSELTIQ (Drug) $4,875
- SOMATULINE DEPOT (Drug) $4,750
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555
Kevin Kalinsky, M.d, M.D
Medical Oncology — Payments: $471,305
Medical Oncology $471,305